Effects of tanshinone on hyperandrogenism and the quality of life in women with polycystic ovary syndrome: protocol of a double-blind, placebo-controlled, randomised trial. by Li, W et al.
Title
Effects of tanshinone on hyperandrogenism and the quality of
life in women with polycystic ovary syndrome: protocol of a
double-blind, placebo-controlled, randomised trial.
Author(s) Shen, W; Zhang, Y; Li, W; Cong, J; Zhou, Y; Ng, EHY; Wu, X
Citation BMJ Open, 2013, v. 3 n. 10, article no. e003646
Issued Date 2013
URL http://hdl.handle.net/10722/203606
Rights Creative Commons: Attribution 3.0 Hong Kong License
Effects of tanshinone on
hyperandrogenism and the quality of
life in women with polycystic ovary
syndrome: protocol of a double-blind,
placebo-controlled, randomised trial
Wenjuan Shen,1 Yuehui Zhang,1 Wei Li,1 Jing Cong,1 Ying Zhou,2 Ernest H Y Ng,3
Xiaoke Wu1
To cite: Shen W, Zhang Y,
Li W, et al. Effects of
tanshinone on
hyperandrogenism and the
quality of life in women with
polycystic ovary syndrome:
protocol of a double-blind,
placebo-controlled,
randomised trial. BMJ Open
2013;3:e003646.
doi:10.1136/bmjopen-2013-
003646
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2013-003646).
Received 24 July 2013
Revised 12 September 2013
Accepted 13 September 2013
1Department of Obstetrics
and Gynecology, First
Affiliated Hospital of
Heilongjiang University of
Chinese Medicine, Harbin,
China
2Heilongjiang University of
Chinese Medicine, Harbin,
China
3Department of Obstetrics
and Gynecology, University of
Hong Kong, Hong Kong,
China
Correspondence to
Prof. Xiaoke Wu;
xiaokewu2002@vip.sina.com
ABSTRACT
Introduction: Polycystic ovary syndrome (PCOS) is
one of the most common endocrine disorders in
reproductive-age women. Chinese herbal medicine has
been used for the treatment of PCOS, but the evidence
for its efficacy and safety is minimal. Tanshinones are
a class of bioactive molecules isolated from Salvia
miltiorrhiza, a commonly used herb in Traditional
Chinese Medicine. This study aims to evaluate the
efficacy of tanshinones on hyperandrogenism and
quality of life in women with PCOS who do not attempt
to conceive.
Methods and analysis: A total of 100 patients will
be recruited and randomised into the tanshinone or
placebo group. Tanshinone or placebo capsules will be
taken orally for 12 weeks. The primary outcome
parameter will be a change in plasma testosterone.
Secondary end points will be changes in human
chorionic gonadotropin-induced androgen response,
insulin resistance, reproductive hormones, fasting lipid
profiles, oral glucose tolerance test, quality of life and
side effects.
Ethics and dissemination: Written informed
consent will be obtained from each participant at the
time of enrolling in the study. The trial has been
approved by the Ethics Committee of First Affiliated
Hospital of Heilongjiang University of Chinese
Medicine. Results will be disseminated through a
publicly accessible website.
Registration details: The study has been registered
at the Chinese Clinical Trials Registry (ChiCTR-TRC-
12002973) and at clinicaltrials.gov (NCT 01452477).
INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of
the most common endocrine disorders in
reproductive-age women. Its prevalence rates
depend on the diagnostic criteria used, but it
can be up to 18% using the Rotterdam
diagnostic criteria.1 PCOS is characterised
by hyperandrogenism, oligo/amenorrhoea
and polycystic ovary morphology and is
often associated with insulin resistance.
Hyperandrogenism is found in 60–80% of
women with PCOS.2 The major clinical and
biochemical features of hyperandrogenism
are hirsutism, acne, alopecia and seborrhoeic
dermatitis; elevated androstenedione, testos-
terone and dehydroepiandrosterone sulfate
(DHEAS) levels; and decreased sex hormone
binding globulin (SHBG) levels. The syn-
drome presents not only with reproductive
manifestations but also has metabolic impli-
cations including insulin resistance, obesity,
dyslipidemia, systemic inﬂammation and type 2
diabetes.3–5
PCOS is a clinical and public health issue
because it adversely affects women’s health and
health-related quality of life and puts a signiﬁ-
cant strain on healthcare resources. PCOS and
related complications are also a tremendous
economic burden, and in 2006 the total
annual cost to treat women with PCOS
between the ages of 14 and 44 years was more
than US$430 million in the USA. Treatments
for hirsutism and diabetes account for 14%
and 40%, respectively, of the total healthcare
costs related to PCOS.6
The long-term therapy for women of PCOS
who do not desire to become pregnant
depends on the speciﬁc clinical presentations
and individual patient goals. Comprehensive
treatment methods for hyperandrogenism and
glucose and lipid metabolic dysfunction
include lifestyle modiﬁcations, diuretic medi-
cines, insulin-sensitising and anticholesteremic
agents and oral contraceptives (OC).7 The ﬁrst-
line treatment in the management of over-
weight or obese women with PCOS is lifestyle
modiﬁcation, which consists of diet and
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exercise, and this can often improve psychological out-
comes, metabolic features and reproductive features.8–11
Lifestyle modiﬁcations can be combined with pharmaco-
logical interventions for optimal results.12 OC can be used
as the ﬁrst-line medical agent in women with PCOS who
have no desire to conceive, and OC can signiﬁcantly
reduce serum androgen concentrations and ameliorate the
androgenic symptoms in the skin. In addition, antiandro-
gens for hyperandrogenism such as spironolactone, ﬂuta-
mide and cyproterone acetate can inhibit androgen-
binding receptors and decrease androgen production.13
When choosing a medication, the side effects of the
various medications must be taken into account, includ-
ing weight gain, fatigue, nausea, oedema, diarrhoea,
sinusitis, hypoglycaemia and kidney toxicity.13 14
Furthermore, some studies have shown that OC might
decrease insulin sensitivity and aggravate glucose and
lipid metabolism.15 16 Therefore, OC have not been
approved by the US Food and Drug Administration for
suppressing androgen production.
Traditional Chinese Medicine (TCM), which origi-
nated in China more than 3000 years ago, is an important
part of complementary medicine (CM). CM includes
many modalities such as Chinese herbal medicine
(CHM), acupuncture, Tai Chi and other therapies. The
theory of TCM is complex and includes Yin and Yang, Qi
and Xue, Zang and Fu and the ﬁve elements. According
to TCM theory, the aetiology and pathogenesis of PCOS
are closely related to ‘blood stasis’ and ‘kidney vacuity’.17
CHM is emerging as one of the most commonly practiced
treatments for PCOS18 and it has been shown to aid in
weight loss and improve the ovulation rate and insulin
resistance as well as improve the patients’ outlook.19
A clinical trial compared the efﬁcacy of metformin and
the Chinese herbal formula ‘Tiangui Fang’ in treating
hyperandrogenism and hyperinsulinism in patients with
PCOS. After treatment for 12 weeks, the Chinese herbal
formula signiﬁcantly lowered the serum testosterone and
insulin levels compared to metformin alone.17 The
mechanisms of some CHM formulations used to treat
PCOS have been elucidated. For example, Gancao (Radix
glycyrrhizae) can inhibit androgen synthesis and Baishao
(Radix paeoniae Alba), Danggui (Radix angelicae Sinensis)
and Danshen (Salvia miltiorrhiza Bunge) improve insulin
sensitivity. Furthermore, Sanqi (Radix Notoginseng), Zelan
(Herba Lycopi) and Zexie (Rhizoma Alismatis) can induce
ovulation.19
Tanshinones are a class of bioactive constituents iso-
lated from S miltiorrhiza (Danshen), which is a com-
monly used herb in TCM. Cryptotanshinone is the
major bioactive tanshinone in the plant and has several
pharmacological effects including anti-inﬂammatory,
antioxidative, anticholinesterase, antibacterial and anti-
platelet aggregation and anticancer activities.20–22 CHM
has been used for the treatment of PCOS, but the evi-
dence for its efﬁcacy and safety is minimal. Animal
experiments showed that cryptotanshinone can induce
favourable alterations in androgen excess and insulin
resistance as well as glucose metabolism,23 but there is
still a lack of scientiﬁc justiﬁcation for the use of tanshi-
none in women with PCOS. In particular, no rando-
mised controlled trials have been performed to evaluate
the use of tanshinone on hyperandrogenism, metabolic
proﬁles or the quality of life in women with PCOS who
do not wish to conceive.
In the proposed study, we seek to evaluate the efﬁcacy
of tanshinone on hyperandrogenism, glucose and lipid
metabolism as well as the quality of life in women with
PCOS who do not attempt to conceive. Our hypothesis
is that tanshinone is effective in the suppression of
androgen production by directly inhibiting ovarian
androgen production and by reducing insulin resistance
and improving the lipid proﬁle.
METHODS AND ANALYSIS
Study design
The study has been registered at the Chinese Clinical
Trials Registry (ChiCTR-TRC-12002973) and at clinical-
trials.gov (NCT 01452477). This is a multicentre, rando-
mised, double-blind and placebo-controlled clinical trial.
Informed written consent will be obtained from eligible
women prior to their participation in this study, and the
recruited women will be randomised into either the tan-
shinone group or the placebo group. We will follow the
CONSORT recommendations in reporting the results.24
Setting and recruitment
This study will be conducted in the outpatient clinics of
four hospitals in mainland China. The principal investi-
gator at each clinic will recruit potentially eligible parti-
cipants who will be informed of the study through
internet, radio, newspaper or television advertisements.
All of the potential participants can get full information
about the study objectives, design and treatment as well
as the beneﬁts and risks of treatment from the investiga-
tors or research coordinators at each site.
Participants
A total of 100 eligible women will be recruited from four
centres in China. They will be examined at the site
centre and enrolled into the trial if they meet the selec-
tion criteria.
Inclusion criteria
1. Presence of PCOS diagnosed based on the Androgen
Excess Society criteria. All participants must have
hyperandrogenism (hirsutism and/or hyperandro-
genaemia) and ovarian dysfunction (oligoanovulation
and/or polycystic ovaries) and must not have other
androgen excess-related disorders. Oligomenorrhoea
is deﬁned as an intermenstrual interval >35 days or
<8 menstrual bleedings in the last year. Amenorrhoea
is deﬁned as an intermenstrual interval >90 days.
Clinical hyperandrogenism is deﬁned as a
Ferriman-Gallwey (FG) score ≥5.25
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2. Within the age range of 18–35 years.
3. No desire to become pregnant within 6 months and
using condoms for contraception.
Exclusion criteria
1. Use of hormonal drugs or other medications in the
past 12 weeks that can affect the results from the
Chinese herbal prescriptions.
2. Other androgen excess endocrine disorders includ-
ing 21-hydroxylase deﬁciency, hyperprolactinaemia,
Cushing syndrome, severe insulin resistance and
thyroid dysfunction.
3. A history of severe cardiac, pulmonary, hepatic, renal
or neurological disease or mental illness.
4. Pregnancy or lactation.
Interventions
Eligible participants will be randomised into either the
tanshinone group or the placebo group. The tanshinone
capsules (1 g 3 times/day, China State Food and Drug
Administration (SFDA) approval number Z13020110) and
placebo capsules will be provided by Hebei Xinglong Xili
Pharmaceutical Co Ltd. The tanshinone and placebo cap-
sules have the same outer packaging, colour, shape and
ﬂavour. Tanshinone or placebo will be administered orally
for 12 weeks. The main pharmaceutical formulation of the
tanshinone capsules is cryptotanshinone, which comprises
90% of the total formulation in the experimental drug.
Study-specific visits and procedures
The trial phase will involve treatment with either tanshinone
or placebo for 12 weeks (ﬁgure 1). Participants will attend
the clinic ﬁve times in total for a screening visit, a baseline
visit, two monthly visits and the end-of-treatment visit.
At the baseline and the end-of-treatment visits, partici-
pants will undergo the following tests between 8:00 and
12:00 after an overnight fast: a human chorionic gonado-
trophin (HCG) stimulation test, a 75 g 2 h oral glucose
tolerance test (OGTT), a hyperinsulinaemic euglycemic
clamp test and measurement of fasting lipid proﬁles and
levels of reproductive hormones. Side effects, adverse
events and other current drug treatments will be
recorded during the visits. An overview of the study visits
is found in table 1.
Study assessment (including questionnaires)
The primary outcome measure is a decrease in basal
serum testosterone concentration. The secondary out-
comes include
1. HCG-induced response of androgens including
17-α-hydroxyprogesterone (17-OHP), androstene-
dione (A2) and testosterone;
2. Insulin resistance as determined by measuring the
glucose disposal rate (GDR) with the hyperinsulinae-
mic euglycemic clamp test;
3. Hyperinsulinaemia as determined by OGTT.
4. Plasma levels of reproductive hormones: oestradiol,
17-OHP, follicle stimulation hormone, luteinising
hormone, SHBG and DHEAS;
5. Fasting glucose and lipid proﬁles: fasting blood
glucose, fasting insulin, C peptide, glycosylated
haemoglobin A1c, cholesterol, triglycerides, high-
density lipoprotein cholesterol and low-density lipo-
protein cholesterol;
6. Weight, blood pressure, waist/hip circumference, FG
score and acne;
7. Side effects and adverse events.
Clinical examination and study tests
Height will be recorded to the nearest 1 cm without
shoes, and weight will be recorded to the nearest
0.01 kg. Patients will be weighed while dressed in light
Figure 1 Flow chart of the
study.
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clothing without shoes. The patient will sit quietly for a
period of 5 min before the blood pressure is taken. The
blood pressure may be taken in either arm using the
appropriate cuff size. Acne lesions26 will be assessed by
trained study personnel who will evaluate the patient’s
face. The areas of the face to be evaluated are the right
forehead, left forehead, right cheek, left cheek and
chin. Hirsutism will be graded according to the modi-
ﬁed FG method by trained study personnel. Patients will
be given the Hirsutism Score form and the study person-
nel will tell the patients to assess the areas outlined on
the form.
HCG test: Ovarian androgen biosynthesis will be mea-
sured with the HCG test. On the morning of the experi-
ment, between 8:00 and 9:00, a single injection of
5000 IU HCG will be given to the patient and blood
samples will be drawn 24 h and 48 h later for assays of
17-OHP, A2 and testosterone.
OGTT test: All participants will undergo an overnight
fast. After ingestion of a 75 g glucose load, blood
samples will be obtained at 0, 30, 60, 90 and 120 min for
determining the glucose and insulin levels.
Hyperinsulinaemic euglycemic clamp: Insulin sensitivity
will be assessed by the hyperinsulinaemic euglycemic
clamp before and after treatment. The hyperinsulinae-
mic euglycemic clamp studies will be performed at the
Huaian Maternal and Child Health Hospital and 60 par-
ticipants will receive clamp examinations. The partici-
pants will undertake a 10–12 h overnight fast. A small
intravenous catheter will be placed in an antecubital
vein for blood sampling and a second catheter will be
inserted into the contralateral forearm for administra-
tion of insulin and glucose infusions. After a 30 min sta-
bilisation period, a priming insulin infusion will be
administered for 3min followed by a constant infusion of
120 mU/m2/min for 120 min. Three minutes after the
start of the priming insulin infusion, 20% dextrose will
be infused at a variable rate to keep blood glucose con-
centrations between 4.5 and 5.0 mmol/L. Blood samples
will be collected every 5 min during the insulin infusion.
GDR (measured as mg/kg/min) is deﬁned as the
amount of glucose required to maintain stable blood
glucose concentrations during the last 30 min of the
clamping. This value will be used as the measure of
insulin resistance.
Questionnaires
All of the participants will be requested to complete the
Polycystic Ovary Syndrome Quality of Life (PCOS-QOL)27
and the Chinese Quality of Life (ChQOL)28 question-
naires before and after treatment.
Randomisation and blinding
Randomisation will be performed through a web-based
randomisation system operated by an independent data
centre (Institute of Basic Research of Clinical Medicine,
China Academy of Chinese Medical Sciences, Beijing).
Participants will be randomly assigned to the tanshinone
group (n=50) or the placebo group (n=50). The identiﬁ-
cation code and random number, which are unique for
each participant, will be given by a web-based system
(http://210.76.97.192:8080/dst/) produced by the inde-
pendent data centre. Participants, investigators and phy-
sicians taking care of participants will be blind to the
assignment.
Data entry and quality control of data
The data will be recorded in the Case Report Forms
(CRFs). The CRFs will be ﬁlled out truly and accurately,
and the electronic versions of the CRFs will be deposited
into a web-based data management system at http://218.
17.160.110:8081/login.aspx.
In order to maintain the quality of the data, we will
adopt valid measures to assure information authenticity,
accuracy and integrity. First, the site investigator or
research coordinator should record or enter informa-
tion accurately and in a timely manner, and every site
investigator must make a monthly check of the accuracy
Table 1 Overview of study visits
Screening
visit
Baseline
visit
Monthly
visit 1
Monthly
visit 2
Monthly visit 3 and
end-of-treatment visit
Physical examination X X
Safety labs (liver profile: ALT/AST, total bilirubin
Renal profile: BUN or creatinine)
X X
Transvaginal ultrasound X X
Fasting phlebotomy for study parameters X X
Hyperinsulinaemic euglycemic clamp X X
Ask about adverse events and concurrent
medications
X X X X
Ask about menstrual period X X X X X
Medication dispensing and accounting X X X
Physical examination: Height, weight, hip and waist circumference, blood pressure, FG score and acne.
Fasting phlebotomy: Serum for the Central Core Laboratory.
Transvaginal ultrasound: Endometrial thickness, ovarian volume, antral follicle count and size of ovarian cysts or developing follicles.
ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; FG score, Ferriman-Gallwey score.
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and timeliness of the recorded information on the
CRFs. Second, the data manager and programmer of
the Data Coordination Center (DCC) will be in charge
of data monitoring and validation and will ensure that
issues arising from the data are resolved quickly and
accurately. Third, unscheduled monitoring of the clin-
ical sites will be important for quality control. These
visits will ensure that the collection method and study
data are standardised, accurate and authentic. The CRFs
will be compared with source documents to make sure
that errors have been resolved without delay. After each
visit, the monitoring report will be distributed to the site
principal investigator. The site visit is an effective action
for maintaining data quality and patient protection.
Sample size calculation and statistical analysis
We hypothesise that the basal serum testosterone level
will be reduced by 10 ng/dL in the tanshinone group
and remain unchanged in the placebo group. We
assume standard deviation of 0.06 of the difference of
two groups. The sample size needed to achieve an 80%
power to perceive a signiﬁcant difference in serum tes-
tosterone concentration between the two treatment
groups at the two-sided 5% level can be estimated with
the parameters α=0.05 and β=0.1. This power analysis
suggests that 40 patients will be needed for each group.
Assuming a 20% dropout rate based on our past experi-
ence, 50 patients will be enrolled in both groups and
100 patients will be enrolled in total.
All data will be analysed by a specialised statistician
using the intent-to-treat approach for the evaluation of
drug efﬁcacy, the per-protocol analysis for adherence
and safety analysis for adverse events. The efﬁcacy of two
treatments (tanshinone vs placebo capsules and within-
participant effects before vs after treatment) will be com-
pared by analysis of variance (ANOVA). Pearson’s χ2 test
will be used to assess the different qualitative data
between the two groups. Statistical evaluation of the data
will be performed using the SPSS programme V.16.0
(SPSS Inc, Chicago, Illinois, USA) and a p value <0.05
will be considered statistically signiﬁcant.
DISCUSSION
As the number of patients with PCOS increases, it is
anticipated that more and more patients will turn to CM
for treatment. CHM can regulate and strengthen the
hormonal systems of the whole body and is a natural
approach for treating PCOS. The signiﬁcant advantages
of CHM are that it provides several options for the safe,
effective, multitargeted treatment of various aspects of
PCOS including hyperandrogenism and poor quality of
life.14 29 30 In our previous studies, we have found that
cryptotanshinone can decrease excessive androgens by
inhibiting steroid hormone production in the theca cells
in the ovary31 32 and also improve insulin resistance and
glucose metabolism.32 33
Tanshinone is used extensively in China for treating
acne because of its antiandrogenic properties. The
purpose of this study is to evaluate whether tanshinone
has a signiﬁcant effect on hyperandrogenism in women
with PCOS and to explore new uses for cryptotanshinone,
the primary biologically active form of tanshinone. This
trial was designed based on the high efﬁcacy and few side
effects of cryptotanshinone. To better evaluate the thera-
peutic effects of tanshinone on hyperandrogenism,
quality of life, insulin resistance and hyperinsulinaemia,
we will use the HCG test, questionnaires (PCOS-QOL
and ChQOL), hyperinsulinaemic euglycemic clamp and
OGTT test. There have been no clinical trials performed
to determine the efﬁcacy of tanshinone for PCOS, and a
well-designed, double-blind, placebo-controlled rando-
mised trial will not only determine the clinical efﬁcacy of
such treatment but also could provide insights into new
evidence-based therapies for PCOS.
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